摘要
目前,肺癌的发病率和死亡率在全世界范围内居首位。静脉血栓栓塞症(venous thromboembolism,VTE)是一种公认的肺癌并发症,也是肺癌患者的主要死因之一。癌症自身因素、患者自身因素以及治疗相关因素都是导致肺癌患者发生VTE的主要原因。肿瘤细胞可产生组织因子(tissue factor, TF)、癌性促凝物质(cancer procoagulant, CP)、炎症因子和细胞因子,从而直接激活凝血;其中TF过度表达是肿瘤患者血栓形成的主要机制之一。2016年美国胸外科医师协会(American College of Chest Physicians, ACCP)发布的第10版肿瘤患者VTE防治指南(AT-10)指出,抗凝治疗是肺癌患者合并VTE的基本治疗措施;其中低分子肝素(low molecular-weight-heparin,LWMH)被认为是首选的抗凝药物,但要注意出血风险。
Lung cancer is the first leading cause of morbidity and mortality in the world. Venous thromboembolism （VTE） is a recognized complication in patients with lung cancer, which is one of the leading cause of death in lung cancer patients. The cancer-related, patient-related and treatment-related factors are the main causes of VTE in lung cancer patients. Malignant cells can directly activate blood coagulation by producing tissue factor （TF）, cancer procoagulance （CP）, inflamma- tory factors and cytokines; And the one of predominant mechanisms in cancer-related thrombosis is the overexpression of TF. The 10th edition of the antithrombotic therapy guidelines for VTE with cancer patients （AT-10） published in 2016 by Ameri- can College of Chest Physicians （APCC） recommended that anticoagulant therapy is the basic treatment for patients with lung cancer complicated with VTE; And low molecular-weight-heparin （LMWH） is preferred as an anticoagulant drug, but can be use with caution due to increasing risk of bleeding.
作者
杜晖
陈军
Hui DU;Jun CHEN(Department of Lung Cancer Surgery,Tianjin Medical University General Hospital,Tianjin 300052,China)
出处
《中国肺癌杂志》
CAS
CSCD
北大核心
2018年第10期784-789,共6页
Chinese Journal of Lung Cancer
基金
国家自然科学基金(No.81773207)
天津自然科学基金重点项目(No.17YFZCSY00840
No.16JCZDJC34200
No.16PTSYJC00160)
天津市人才发展特殊支持计划高层次创新创业团队基金资助~~
关键词
肺肿瘤
静脉血栓栓塞症
发生
抗凝治疗
低分子肝素
Lung neoplasms
Venous thromboembolism （VTE）
Occurrence
Anticoagulant therapy
Low molecular weight heparin （LMWH）
